Product IntroductionBioactivity英文名:
Epothilone D描述: Epothilone D (KOS 862) is an effective microtubule stabilizer.
動(dòng)物實(shí)驗(yàn): Groups of mice (n=3) receive intraperitoneal (i.p.) injections of 3.7 mg/kg of Epothilone D (epoD) dissolved in 100% DMSO, followed by euthanization using approved at times ranging from 0.25 h to 24 h. In another study, groups of mice (n=3) receive injections of 3 mg/kg of epoD in 100% DMSO followed by euthanization 4, 6 and 10 days later. The Epothilone D (epoD) levels in the brain and blood samples are determined using LC-MS/MS protocols. Groups (n=10-13) of 3-month old PS19 tau Tg mice or 3-month old non-Tg littermates are administered weekly i.p. injections of 1 mg/kg epoD, 3 mg/kg of Epothilone D (epoD) or vehicle (DMSO), for a total of 3 months. Animals are monitored for signs of abnormal behavior or distress and are weighed weekly. After final dosing, the mice undergo motor function and cognitive testing. After euthanization, brains and optic nerve (ON) are recovered for immunohistochemical analyses. A subset of mice from each group also undergo necropsy evaluation with organ weights recorded [2].
體外活性: Epothilone D is a more potent microtubule stabilizer in vitro than epothilone A or B. In vitro, Epothilone D has shown potent cytotoxicity in a panel of human tumor cell lines, with similar potency to paclitaxel. Epothilone D also shows a definite advantage over paclitaxel in drug-resistant cell lines and retained its cytotoxicity against a multidrug-resistant cell line over-expressing P-glycoprotein [1].
體內(nèi)活性: To evaluate whether Epothilone D improves MT and axonal function in PS19 mice, groups of 3-month old male PS19 mice received weekly i.p. injections of vehicle or Epothilone D (1 mg/kg or 3 mg/kg) for a total of 3 months. In addition, 3-month old non-Tg littermates received 3 mg/kg Epothilone D or vehicle. The 3 mg/kg Epothilone D dose corresponds to ~10-fold less than that used in Phase II clinical study, which should minimize side-effects such as neutropenia that are observed with MT-stabilizing drugs in human subjects. PS19 and WT mice that receive Epothilone D show no signs of drug intolerance. Indeed, all drug-treated mice exhibited weight gain that is indistinguishable from vehicle-treated animals. Likewise, relative organ weights are similar in vehicle- and Epothilone D-treated mice. The motor performance of Epothilone D-treated mice, assessed using a standard rotarod test, is not significantly different from vehicle-treated cohorts [2].
存儲(chǔ)條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: DMSO : 300 mg/mL (610.15 mM)
關(guān)鍵字:
KOS-862 |
KOS862 |
Epothilone D相關(guān)產(chǎn)品:
Colcemid |
Colchicine |
MMAD |
Auristatin F |
LY3372689 |
Tubulin polymerization-IN-43 |
WAY-118959-A |
Tubulin inhibitor 24 |
Methylene Blue trihydrate |
OSIP-486823bio-equip.com
TargetMol(陶術(shù))作為一家全球性的生物醫(yī)藥領(lǐng)域高科技企業(yè),我們致力于為高校、研究所、醫(yī)院、企業(yè)等各類生物醫(yī)藥研發(fā)機(jī)構(gòu)提供優(yōu)質(zhì)的產(chǎn)品和服務(wù),為全球醫(yī)藥科學(xué)家更高效地完成科研工作助力?商峁20,000+種 抑制劑和激動(dòng)劑 、800+種 化合物庫(kù) 、19,000+種 天然產(chǎn)物 ,以及9,000+種 重組蛋白 、多種 多肽 、抗體 和 生命科學(xué)試劑盒 等。此外,在上海,TargetMol研發(fā)中心配備了 CADD & AIDD研究中心、藥理實(shí)驗(yàn)室和藥物化學(xué)合成 平臺(tái)三大技術(shù)中心,可提供虛擬篩選、化合物活性測(cè)試、分子間結(jié)合力檢測(cè)和化合物結(jié)構(gòu)優(yōu)化等技術(shù)服務(wù),多方位滿足用戶的研發(fā)需求。